Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development...

Biogen (UK) Ltd is a leading UK owner and operator of anaerobic digestion and composting plants based in Bedfordshire. It is responsible for the construction...

funded by Cure SMA. Starting in 2012, Ionis partnered with Biogen on development and, in 2015, Biogen acquired an exclusive license to the drug for a US$75...

conducted by Fumapharm in collaboration with Biogen Idec; Fumapharm was subsequently acquired by Biogen Idec in 2006. Aditech Pharma in Sweden had also...

esters, primarily dimethyl fumarate, and marketed as Fumaderm by Biogen Idec in Europe. Biogen would later go on to develop the main ester, dimethyl fumarate...

people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai. Aducanumab is given via intravenous infusion. Aducanumab was...

S2CID 46326042. "Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis" (Press release). Biogen Idec....

as CEO between 2021 and 2022. He was formerly the president and CEO of Biogen Idec until he retired effective June 8, 2010. At the same time, he started...

merged with Biogen to form the third largest biotech firm in the United States. Rastetter was Executive Chair of the new company, Biogen IDEC, from 2003...

Biologics (50 per cent plus one share) and the U.S.-based Biogen Idec (50 per cent). In 2014, Biogen Idec agreed to commercialize future anti-TNF biosimilar...

developed by Ionis Pharmaceuticals and was licensed to, and co-developed by, Biogen. The effectiveness of tofersen was evaluated in a 28-week, randomized, double-blind...

a marketing manager for Raychem. From 1997 to 2006, Anderson worked at Biogen in multiple countries, including, Ireland, the U.S., and the U.K., holding...

Tools & Services Minneapolis, Minnesota 2021-08-30 0000842023 1976 BIIB Biogen Health Care Biotechnology Cambridge, Massachusetts 2003-11-13 0000875045...

from 2017 to 2023. Scangos was previously the chief executive officer of Biogen from 2010 to 2016 and of Exelixis from 1996 to 2010. Prior to joining industry...

private equity fund backed by Ernesto Bertarelli and his family. He joined Biogen as President and Chief Executive Officer and member of the Board of Directors...

Tower, Global Partners, Thermo Fisher Scientific, State Street Corporation, Biogen, Eversource Energy, and Boston Scientific. CNBC's list of "Top States for...

T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe. Daclizumab...

Villalobos is a medicinal chemist and senior pharmaceutical executive at Biogen. Villalobos was raised in Panama City. She received her BS in chemistry...

antibodies targeting amyloid. Lecanemab was jointly developed by Eisai and Biogen. It was granted accelerated approval for medical use in the United States...

Dickinson UK Ltd Beiersdorf – Beiersdorf UK Ltd Berk – TEVA UK Ltd Biogen – Biogen Idec Boehringer Ingelheim – Boehringer Ingelheim Ltd Boots – Boots...

Cambridge, Massachusetts-headquartered multinational biotechnology company, Biogen for nearly $6.5 billion. The purchase was completed on September 26 and...

Aerospace & Defense Baker Hughes BKR Energy Oil & Gas Equipment & Services Biogen BIIB Health Care Biotechnology Booking Holdings BKNG Consumer Discretionary...

2016 Biogen announced that it would spin off its hemophilia drug business (Eloctate and Alprolix) into a separate public company. In August, Biogen announced...

(headquarters) Biocell Center, in Medford (North American headquarters) Biogen Idec, in Weston (North American headquarters) Carl Zeiss SMT, in Peabody...

initially developed by Ionis, which partnered with Biogen on development starting in 2012; in 2015 Biogen acquired an exclusive license to the drug for a...

February 2013, Elan decided to dispose of the rights to sell Tysabri to Biogen Idec for $3.25 billion. In neurology, Elan was focused on building upon...

receptor positive allosteric modulator. SAGE-324 was being developed by Biogen for the treatment of essential tremor. Its development was discontinued...

regulations in 1977. This led to regulatory certainty and acceptance when Biogen opened a lab in 1982, in contrast to the hostility that caused the Genetic...

"a polyethylene glycol conjugated anti-CD40L Fab fragment" developed by Biogen for systemic lupus erythematosus. Chamberlain, Chris; Colman, Peter J; Ranger...

the following year a partnership was formed with Syntonix (subsequently Biogen Idec) to jointly develop a drug for hemophilia B, a long-lasting recombinant...